ArticleJournal for immunotherapy of cancer2025

Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry.

Daniel J Landsburg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.